In a clinical trial for pancreatic ductal adenocarcinoma, combination treatment with the CCR2 antagonist BMS-813160 and anti-PD-1 was determined to be safe with only one grade 3 or higher adverse event in a single patient (Christenson et al., 2023). Here, CCR2 is linked to pancreatic ductal adenocarcinoma.